Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RZ9V
|
|||
| Drug Name |
IDH305
|
|||
| Synonyms |
DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81
Click to Show/Hide
|
|||
| Indication | Advanced malignancy [ICD-11: 2A00-2F9Z; ICD-10: C00-C96; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Novartis Oncology East Hanover, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H22F4N6O2
|
|||
| Canonical SMILES |
CC1=CC(=NC=C1C2=CC(=NC=C2)C(F)(F)F)C(C)NC3=NC=CC(=N3)N4C(COC4=O)C(C)F
|
|||
| InChI |
1S/C23H22F4N6O2/c1-12-8-17(30-10-16(12)15-4-6-28-19(9-15)23(25,26)27)14(3)31-21-29-7-5-20(32-21)33-18(13(2)24)11-35-22(33)34/h4-10,13-14,18H,11H2,1-3H3,(H,29,31,32)/t13-,14-,18+/m0/s1
|
|||
| InChIKey |
DCGDPJCUIKLTDU-SUNYJGFJSA-N
|
|||
| CAS Number |
CAS 1628805-46-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxalosuccinate decarboxylase (IDH1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Warburg Effect | |||
| WikiPathways | TCA Cycle and PDHc | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Peroxisomal lipid metabolism | ||||
| Glutathione metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.